Drug Patents owned by Boehringer Ingelheim

1. Drug name - ATROVENT HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447 BOEHRINGER INGELHEIM Inhaler device Jan, 2030

(7 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.021MG/INH AEROSOL, METERED;INHALATION Prescription

2. Drug name - COMBIVENT RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties Aug, 2024

(1 year, 10 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function May, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device Oct, 2026

(4 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE/INH;0.02MG/INH SPRAY, METERED;INHALATION Prescription

3. Drug name - GILOTRIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43431 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jan, 2026

(3 years from now)

US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(7 years from now)

CN101402631A BOEHRINGER INGELHEIM Amino Quinazoline Dimaleate, Method For Production Thereof And Use Thereof
Dec, 2013

(8 years ago)

CN1481370A BOEHRINGER INGELHEIM Quinazoline Derivatives, Pharmaceutical Compositions Containing These Compounds, Their Use And Process For Their Manufacture
Dec, 2021

(9 months ago)

CN1277822C BOEHRINGER INGELHEIM Quinazoline Derivatives, Pharmaceutical Compositions Containing These Compounds, Their Use And Process For Their Manufacture
Dec, 2021

(9 months ago)

CN1867564A BOEHRINGER INGELHEIM Method For Preparing Amino Croton Radical Compound
Oct, 2024

(2 years from now)

CN1867564B BOEHRINGER INGELHEIM Method For Preparing Amino Croton Based Compound
Oct, 2024

(2 years from now)

IN224186B BOEHRINGER INGELHEIM Quinazoline Compounds And Process Thereof
Dec, 2021

(9 months ago)

IN200300822P1 BOEHRINGER INGELHEIM Quinazoline Compounds And Process Thereof
Dec, 2021

(9 months ago)

EP2508521B1 BOEHRINGER INGELHEIM Method For The Production Of Amino Crotonyl Compounds
Oct, 2024

(2 years from now)

EP2508521A2 BOEHRINGER INGELHEIM Dimaleat Of An Amino Crotonyl Compound And Method Of Production Thereof
Oct, 2024

(2 years from now)

EP1678165B1 BOEHRINGER INGELHEIM Method For The Production Of Amino Crotonyl Compounds
Oct, 2024

(2 years from now)

EP2508521A3 BOEHRINGER INGELHEIM Method For The Production Of Amino Crotonyl Compounds
Oct, 2024

(2 years from now)

EP1678165A2 BOEHRINGER INGELHEIM Method For The Production Of Amino Crotonyl Compounds
Oct, 2024

(2 years from now)

EP1345910B1 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

EP1345910A1 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

EP1345910B9 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them Jul, 2026

(3 years from now)

US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases Nov, 2026

(4 years from now)

US9539258

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases May, 2027

(4 years from now)

US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992 Dec, 2029

(7 years from now)

US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds Apr, 2030

(7 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992 Jun, 2030

(7 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient Jul, 2030

(7 years from now)

US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient Jan, 2031

(8 years from now)

Drugs and Companies using AFATINIB DIMALEATE ingredient

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

4. Drug name - GLYXAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

CN1930141A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2014

(8 years ago)

CN103450129A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103450129B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103467423A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same
Sep, 2021

(1 year, 22 days ago)

CN103467423B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN101503408B BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds
Aug, 2023

(10 months from now)

CN1675212A BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN105001222B BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN100522962C BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN101503408A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound
Aug, 2023

(10 months from now)

CN101503409A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2023

(10 months from now)

CN102964347B BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN102964347A BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN101503409B BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations
Aug, 2023

(10 months from now)

CN105001222A BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN101155794B BOEHRINGER INGELHEIM 1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine
May, 2026

(3 years from now)

CN101155794A BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

IN200500567P1 BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN243301B BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN200604844P1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

IN268846B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

EP1828216B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1828216A2 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1888552A1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1888552B1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1532149B9 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149A2 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149B1 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1730131B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

EP1730131A1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations May, 2027

(4 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors May, 2027

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Oct, 2029

(7 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;5MG TABLET;ORAL Prescription
25MG;5MG TABLET;ORAL Prescription

5. Drug name - JARDIANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

CN1930141A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2014

(8 years ago)

CN103450129B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103450129A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103467423A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same
Sep, 2021

(1 year, 22 days ago)

CN103467423B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN101155794B BOEHRINGER INGELHEIM 1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine
May, 2026

(3 years from now)

CN101155794A BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

IN200604844P1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

IN268846B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

EP1828216B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1828216A2 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1888552A1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1888552B1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1730131A1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

EP1730131B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Oct, 2029

(7 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof May, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription

6. Drug name - JENTADUETO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

CN101503408B BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds
Aug, 2023

(10 months from now)

CN1675212A BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN102964347B BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN102964347A BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN101503409A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2023

(10 months from now)

CN105001222B BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN100522962C BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN101503409B BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations
Aug, 2023

(10 months from now)

CN105001222A BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN101503408A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound
Aug, 2023

(10 months from now)

IN200500567P1 BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN243301B BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

EP1532149B9 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149A2 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149B1 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US10973827 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation May, 2030

(7 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor Jun, 2030

(7 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET;ORAL Prescription
2.5MG;500MG TABLET;ORAL Prescription
2.5MG;850MG TABLET;ORAL Prescription

7. Drug name - JENTADUETO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

CN101503408B BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds
Aug, 2023

(10 months from now)

CN1675212A BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN102964347B BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN102964347A BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN101503409A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2023

(10 months from now)

CN105001222B BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN100522962C BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN101503409B BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations
Aug, 2023

(10 months from now)

CN105001222A BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN101503408A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound
Aug, 2023

(10 months from now)

IN200500567P1 BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN243301B BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

EP1532149B9 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149A2 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149B1 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors May, 2027

(4 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation May, 2030

(7 years from now)

US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof Mar, 2033

(10 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus; Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin; method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

8. Drug name - MICARDIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003679 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system Oct, 2022

(3 days from now)

Drugs and Companies using TELMISARTAN ingredient

Treatment: Treatment or prevention of stroke

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription

9. Drug name - MIRAPEX ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7695734 BOEHRINGER INGELHEIM Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof Apr, 2028

(5 years from now)

US8679533 BOEHRINGER INGELHEIM Pramipexole once-daily dosage form Sep, 2029

(6 years from now)

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
0.375MG TABLET, EXTENDED RELEASE;ORAL Prescription
0.75MG TABLET, EXTENDED RELEASE;ORAL Prescription
1.5MG TABLET, EXTENDED RELEASE;ORAL Prescription
2.25MG TABLET, EXTENDED RELEASE;ORAL Prescription
3MG TABLET, EXTENDED RELEASE;ORAL Prescription
3.75MG TABLET, EXTENDED RELEASE;ORAL Prescription
4.5MG TABLET, EXTENDED RELEASE;ORAL Prescription

10. Drug name - OFEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(1 year, 4 months from now)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(2 years from now)

CN1391557A BOEHRINGER INGELHEIM 6-Position Substituted Dihydroindole Ketone, Its Preparation And Its Use As A Pharmaceutical Composition
Oct, 2020

(1 year, 11 months ago)

CN100455568C BOEHRINGER INGELHEIM 6-Position Substituted Dihydroindole Ketone, Its Preparation And Its Use As A Pharmaceutical Composition
Oct, 2020

(1 year, 11 months ago)

CN100351235C BOEHRINGER INGELHEIM 2-Ketone-Ethyl Sulfonate Of A Pharmaceutical Composition And Its Preparation
Jul, 2023

(9 months from now)

CN1671660A BOEHRINGER INGELHEIM 3-Z - [4 - (1 - (N - ((4-Methyl-Piperazin - -1 - Yl) - Methyl Carbonyl) - N-Methyl-Amino) - Phenylamino)--1 - Phenyl-Methylene]--6 - Methoxycarbonyl - -2 - Indolinone-Ethane Sulfonic Acid Salts And Their Use As A Pharmaceutical Composition
Jul, 2023

(9 months from now)

IN200200362P3 BOEHRINGER INGELHEIM Indolinones Substituted In 6-Position, Preparation, And Their Use As Pharmaceutical Composition
Oct, 2020

(1 year, 11 months ago)

IN210415B BOEHRINGER INGELHEIM Indolinones Of General Formula I
Oct, 2020

(1 year, 11 months ago)

EP1224170B9 BOEHRINGER INGELHEIM 6-Position Substituted Indoline, Production And Use Thereof As A Medicament
Oct, 2020

(1 year, 11 months ago)

EP1224170B1 BOEHRINGER INGELHEIM 6-Position Substituted Indoline, Production And Use Thereof As A Medicament
Oct, 2020

(1 year, 11 months ago)

EP1224170A1 BOEHRINGER INGELHEIM 6-Position Substituted Indoline, Production And Use Thereof As A Medicament
Oct, 2020

(1 year, 11 months ago)

EP1527047B1 BOEHRINGER INGELHEIM 3-Z- 1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Me Thyl-Amino)-Anilino)-1-Phenyl-Methylene -6-Methoxycarbonyl-2 -Indolinone-Monoethanesulphonate And The Use Thereof As A Pharmaceutical Composition
Jul, 2023

(9 months from now)

EP1527047A1 BOEHRINGER INGELHEIM 3-Z- 1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Me Thyl-Amino)-Anilino)-1-Phenyl-Methylene -6-Methoxycarbonyl-2 -Indolinone-Monoethanesulphonate And The Use Thereof As A Pharmaceutical Composition
Jul, 2023

(9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases Dec, 2025

(3 years from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative Jun, 2029

(6 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative Jun, 2029

(6 years from now)

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

11. Drug name - PRADAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(2 years from now)

CN102167695B BOEHRINGER INGELHEIM Benzimidazole-Carbonyl-Pyridine-Amino-Ehtyl-Propionate Hemihyrate And Use Thereof
Aug, 2024

(1 year, 10 months from now)

CN1845917A BOEHRINGER INGELHEIM 3 - [(2 - {[4 - (Methoxy Carbonyl Amino-Imino-Methyl) - Phenylamino] - Methyl} - 1-Methyl-1-H-Benzimidazole-5-Carbonyl) - Pyridin-2-Yl-Amino] - Ethyl Propionate-Mesylate And Its Use As A Pharmaceutical
Aug, 2024

(1 year, 10 months from now)

CN1845917B BOEHRINGER INGELHEIM 3 - [(2 - {[4 - (Hexyloxy Carbonyl Amino-Imino-Methyl) - Benzene-Amino] - Methyl} -1--1H - Benzimidazole - -5 - Carbonyl) - Pyridin - -2 - Yl-Amino] - Ethyl Propionate Mesylate And Its Use As A Pharmaceutical
Aug, 2024

(1 year, 10 months from now)

CN102167695A BOEHRINGER INGELHEIM Benzimidazole Carbonyl Pyridine Amino Ethyl Propionate Semihydrate And Application Thereof
Aug, 2024

(1 year, 10 months from now)

IN200600924P1 BOEHRINGER INGELHEIM 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) Phenylamino]Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)Pyridin-2-Ylamino]Propionic Acid Ethylester Methansulfonate And Its Use As A Medicament
Aug, 2024

(1 year, 10 months from now)

IN256941B BOEHRINGER INGELHEIM Process For Preparing 324Hexyloxycarbonyla Minoiminomethylpheny Laminomethyl-1-Methyl-1H-Benzimidazol5Carbon Ylpyridine2Ylaminopro Pionate Methanesulfonate
Aug, 2024

(1 year, 10 months from now)

EP2060569B1 BOEHRINGER INGELHEIM Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino]-Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino]-Propionate Methanesulfonate Hemihydrate And Its Use As A Medicament
Aug, 2024

(1 year, 10 months from now)

EP2060569A1 BOEHRINGER INGELHEIM Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino]-Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino]-Propionate Methanesulfonate Hemihydrate And Its Use As A Medicament
Aug, 2024

(1 year, 10 months from now)

EP1660482A1 BOEHRINGER INGELHEIM 3-[(2-{ 4-(Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino] -Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino -Propionic Acid Ethyl Ester Methane Sulphonate And Use Thereof As A Medicament
Aug, 2024

(1 year, 10 months from now)

EP1660482B1 BOEHRINGER INGELHEIM 3-[(2-{ 4-(Hexyloxycarbonylamino-Imino-Methyl)-Phenylamino] -Methyl}-1-Methyl-1H-Benzimidazol-5-Carbonyl)-Pyridin-2-Yl-Amino -Propionic Acid Ethyl Ester Methane Sulphonate And Use Thereof As A Medicament
Aug, 2024

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925174 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof Jun, 2023

(8 months from now)

US9925174

(Pediatric)

BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof Dec, 2023

(1 year, 2 months from now)

US7932273

(Pediatric)

BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament Mar, 2026

(3 years from now)

US7866474 BOEHRINGER INGELHEIM Film container Aug, 2027

(4 years from now)

US7866474

(Pediatric)

BOEHRINGER INGELHEIM Film container Mar, 2028

(5 years from now)

US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Jan, 2031

(8 years from now)

US9034822

(Pediatric)

BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds Jul, 2031

(8 years from now)

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE CAPSULE;ORAL Prescription
EQ 110MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

12. Drug name - SPIRIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8022082 BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation Jan, 2026

(3 years from now)

US8022082

(Pediatric)

BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation Jul, 2026

(3 years from now)

US7694676 BOEHRINGER INGELHEIM Dry powder inhaler Mar, 2027

(4 years from now)

US7694676

(Pediatric)

BOEHRINGER INGELHEIM Dry powder inhaler Sep, 2027

(4 years from now)

US9010323 BOEHRINGER INGELHEIM Inhaler and sieve for an inhaler Apr, 2030

(7 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Treatment: Administration of an inhalable powder comprising tiotropium via device

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.018MG BASE/INH POWDER;INHALATION Prescription

13. Drug name - SPIRIVA RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties Aug, 2024

(1 year, 10 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties Feb, 2025

(2 years from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function May, 2025

(2 years from now)

US7896264

(Pediatric)

BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function Nov, 2025

(3 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device Oct, 2026

(4 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2027

(4 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device Apr, 2027

(4 years from now)

US9027967

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component Oct, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component Sep, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Oct, 2030

(8 years from now)

US8733341

(Pediatric)

BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Apr, 2031

(8 years from now)

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.00125MG BASE/INH SPRAY, METERED;INHALATION Prescription
EQ 0.0025MG BASE/INH SPRAY, METERED;INHALATION Prescription

14. Drug name - STIOLTO RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(1 year, 1 month from now)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(1 year, 2 months from now)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(4 years from now)

CN1713914A BOEHRINGER INGELHEIM New Medicine For Treating Chronic Obstructive Pulmonary Disease
Aug, 2010

(12 years ago)

CN101133039A BOEHRINGER INGELHEIM Novel Enantiomer Pure Beta-Agonists And Preparation Method And Use Thereof In Medicine Form
Mar, 2013

(9 years ago)

CN102827097B BOEHRINGER INGELHEIM Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form
May, 2025

(2 years from now)

CN102827097A BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form
May, 2025

(2 years from now)

IN200501999P1 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Disease
Nov, 2023

(1 year, 1 month from now)

IN225518B BOEHRINGER INGELHEIM Novel Substitued [1,1-Dimethyl-Ethyl-Amino)-I-Hydroxy-Ethyl]-6-Hydroxy-4H-Benzo[1,4]Oxazin-3-Ones) Compounds
Nov, 2023

(1 year, 1 month from now)

EP1562603B3 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1562603B1 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1562603A2 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1789405B1 BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug
May, 2025

(2 years from now)

EP1789405A1 BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease Nov, 2023

(1 year, 1 month from now)

US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease Nov, 2023

(1 year, 1 month from now)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties Aug, 2024

(1 year, 10 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties Feb, 2025

(2 years from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments May, 2025

(2 years from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function May, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device Oct, 2026

(4 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2027

(4 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device Apr, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component Sep, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Oct, 2030

(8 years from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

Treatment: Treatment of copd

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH SPRAY, METERED;INHALATION Prescription

15. Drug name - STRIVERDI RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(1 year, 1 month from now)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(1 year, 2 months from now)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(4 years from now)

CN1713914A BOEHRINGER INGELHEIM New Medicine For Treating Chronic Obstructive Pulmonary Disease
Aug, 2010

(12 years ago)

CN101133039A BOEHRINGER INGELHEIM Novel Enantiomer Pure Beta-Agonists And Preparation Method And Use Thereof In Medicine Form
Mar, 2013

(9 years ago)

CN102827097B BOEHRINGER INGELHEIM Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form
May, 2025

(2 years from now)

CN102827097A BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form
May, 2025

(2 years from now)

IN200501999P1 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Disease
Nov, 2023

(1 year, 1 month from now)

IN225518B BOEHRINGER INGELHEIM Novel Substitued [1,1-Dimethyl-Ethyl-Amino)-I-Hydroxy-Ethyl]-6-Hydroxy-4H-Benzo[1,4]Oxazin-3-Ones) Compounds
Nov, 2023

(1 year, 1 month from now)

EP1562603B3 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1562603B1 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1562603A2 BOEHRINGER INGELHEIM Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases
Jul, 2020

(2 years ago)

EP1789405B1 BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug
May, 2025

(2 years from now)

EP1789405A1 BOEHRINGER INGELHEIM Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease Nov, 2023

(1 year, 1 month from now)

US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease Nov, 2023

(1 year, 1 month from now)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties Aug, 2024

(1 year, 10 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments May, 2025

(2 years from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function May, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device Oct, 2026

(4 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Oct, 2030

(8 years from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0025MG BASE/INH SPRAY, METERED;INHALATION Prescription

16. Drug name - SYNJARDY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

CN1930141A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2014

(8 years ago)

CN103450129B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103450129A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103467423A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same
Sep, 2021

(1 year, 22 days ago)

CN103467423B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN101155794B BOEHRINGER INGELHEIM 1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine
May, 2026

(3 years from now)

CN101155794A BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

IN200604844P1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

IN268846B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

EP1828216B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1828216A2 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1888552A1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1888552B1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1730131A1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

EP1730131B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610489 BOEHRINGER INGELHEIM Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof Sep, 2030

(7 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;1GM TABLET;ORAL Prescription
5MG;500MG TABLET;ORAL Prescription
12.5MG;1GM TABLET;ORAL Prescription
12.5MG;500MG TABLET;ORAL Prescription

17. Drug name - SYNJARDY XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

CN1930141A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2014

(8 years ago)

CN103450129B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103450129A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103467423A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same
Sep, 2021

(1 year, 22 days ago)

CN103467423B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN101155794B BOEHRINGER INGELHEIM 1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine
May, 2026

(3 years from now)

CN101155794A BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

IN200604844P1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

IN268846B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

EP1828216B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1828216A2 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1888552A1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1888552B1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1730131A1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

EP1730131B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions Mar, 2032

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
12.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
25MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

18. Drug name - TRADJENTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

CN101503408B BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds
Aug, 2023

(10 months from now)

CN1675212A BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN102964347B BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN102964347A BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN101503409A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2023

(10 months from now)

CN105001222B BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN100522962C BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN101503409B BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations
Aug, 2023

(10 months from now)

CN105001222A BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN101503408A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound
Aug, 2023

(10 months from now)

IN200500567P1 BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN243301B BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

EP1532149B9 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149A2 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149B1 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations May, 2027

(4 years from now)

US9486526 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy Aug, 2029

(6 years from now)

US10034877 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy Aug, 2029

(6 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor Jun, 2030

(7 years from now)

US8853156 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy Mar, 2031

(8 years from now)

Drugs and Companies using LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone; method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment; Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription

19. Drug name - TRIJARDY XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

CN1930141A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2014

(8 years ago)

CN103450129A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103450129B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2021

(1 year, 4 months ago)

CN103467423A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581A BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN103435581B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Phenyl Derivatives, Medicaments Containing Said Compounds, Use Thereof, And Method For Manufacturing The Same
Sep, 2021

(1 year, 22 days ago)

CN103467423B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Sep, 2021

(1 year, 22 days ago)

CN101503408B BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compounds
Aug, 2023

(10 months from now)

CN1675212A BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Its Purpose As A Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN105001222B BOEHRINGER INGELHEIM 8 - (3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN100522962C BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-1-Yl] - Xanthine, Its Preparation Method And Purpose As Medicine Preparation
Aug, 2023

(10 months from now)

CN101503408A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines Compound
Aug, 2023

(10 months from now)

CN101503409A BOEHRINGER INGELHEIM 8-(3-Amino-Piperidin-1-Yl)-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2023

(10 months from now)

CN102964347B BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN102964347A BOEHRINGER INGELHEIM 8 - (3 - - Piperidine-1 - - Yl] - Xanthine Compound, Preparation Method And Use Thereof As Pharmaceutical Preparation
Aug, 2023

(10 months from now)

CN101503409B BOEHRINGER INGELHEIM 8 - [3-Amino-Piperidin-L-Yl] - Xanthines, Processes For Their Preparation And Their Use As Pharmaceutical Preparations
Aug, 2023

(10 months from now)

CN105001222A BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, Preparation Method Thereof And Application Thereof As Medicament
Aug, 2023

(10 months from now)

CN101155794B BOEHRINGER INGELHEIM 1 - -4-[Beta] -D - Glucopyranose - -1) -2-[4 - ((S) - Tetrahydrofuran - -3 - Yloxy) - Benzyl] - Crystal Form Of Benzene, Preparation Method Thereof And Use For Preparing Medicine
May, 2026

(3 years from now)

CN101155794A BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(Betal-D-Glucopyranos-1-Radical)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

IN200500567P1 BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN243301B BOEHRINGER INGELHEIM 8-(3-Aminopiperidin-1-Yl)-Xanthine Compounds
Aug, 2023

(10 months from now)

IN200604844P1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

IN268846B BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzenol Derivative, Drug Containing Said Compound, The Use Thereof And Method For The Production Thereof
Mar, 2025

(2 years from now)

EP1828216B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1828216A2 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzene Derivatives, Medicaments Containing Such Compounds, Their Use And Process For Their Manufacture
Dec, 2025

(3 years from now)

EP1888552A1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1888552B1 BOEHRINGER INGELHEIM Crystalline Form Of 1-Chloro-4-(ß-D-Glucopyranos-1-Yl)-2-[4-((S)-Tetrahydrofuran-3-Yloxy)-Benzyl]-Benzene, A Method For Its Preparation And The Use Thereof For Preparing Medicaments
May, 2026

(3 years from now)

EP1532149B9 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149A2 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1532149B1 BOEHRINGER INGELHEIM 8-[3-Amino-Piperidin-1-Yl]-Xanthines, The Production Thereof And The Use Of The Same As Medicaments
Aug, 2026

(3 years from now)

EP1730131B1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

EP1730131A1 BOEHRINGER INGELHEIM Glucopyranosyl-Substituted Benzol Derivatives, Drugs Containing Said Compounds, The Use Thereof And Method For The Production Thereof
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions Aug, 2023

(10 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation Apr, 2029

(6 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate Oct, 2029

(7 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation May, 2030

(7 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2030

(7 years from now)

US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions Mar, 2032

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes using a pharmaceutical composition comprising linagliptin, metformin, empagliflozin and a basic amino acid; Method of treating type 2 diabetes mellitus using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Method of treating a type 2 diabetes mellitus patient with insufficient glycemic control despite therapy with metformin using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
12.5MG;2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
25MG;5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

20. Drug name - VIRAMUNE XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8460704 BOEHRINGER INGELHEIM Extended release formulation of nevirapine Mar, 2029

(6 years from now)

Drugs and Companies using NEVIRAPINE ingredient

Treatment: Treatment of hiv-1 by once daily administration

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET, EXTENDED RELEASE;ORAL Prescription
400MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.